Cara Therapeutics, Inc. (CARA)
| Market Cap | 766.88M |
| Revenue (ttm) | 123.29M |
| Net Income (ttm) | 8.35M |
| Shares Out | 50.06M |
| EPS (ttm) | 0.17 |
| PE Ratio | 91.65 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 343,177 |
| Open | 15.40 |
| Previous Close | 15.31 |
| Day's Range | 15.27 - 15.62 |
| 52-Week Range | 11.22 - 29.65 |
| Beta | 1.07 |
| Analysts | Buy |
| Price Target | 26.33 (+69.0%) |
| Est. Earnings Date | Nov 8, 2021 |
About CARA
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-assoc...
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for CARA stock is "Buy." The 12-month stock price forecast is 26.33, which is an increase of 69.00% from the latest price.
News
Is Cara Therapeutics Stock a Buy After Its First FDA Drug Approval
There's good news at long last for the beaten-down biotech stock.
Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New molecular entity approvals – ...
Why Cara Therapeutics Shot Higher Today
The biotech gets an important nod from a top regulator.
CARA Stock: The Huge FDA News Sending Cara Therapeutics Skyrocketing Today
Shares of CARA stock are ticking higher on Tuesday after the Cara Therapeutics' injection treatment was approved by the FDA. The post CARA Stock: The Huge FDA News Sending Cara Therapeutics Skyrocketing...
Biotech Stock Takes on Technical Ceiling After FDA Okay
Care Therapeutics Inc (NASDAQ:CARA) is seeing a influx of options activity today, following news that the U.S. Food and Drug Administration (FDA) approved its Korsuva difelikefalin injection to treat mo...
CARA Drug Wins FDA Nod for Pruritus Associated With CKD
CARA gets a significant boost with FDA approval for Korsuva injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.
Why Is Cara Therapeutics Stock Trading Higher Today?
Cara Therapeutics Inc (NASDAQ: CARA) is trading higher Tuesday after the company, and Vifor Pharma, announced the U.S. Food and Drug Administration approved KORSUVA for injection for the treatment of mo...
See Why Cara Therapeutics (CARA) Stock Is Moving Higher On Tuesday
The FDA has approved Cara Therapeutics Inc (NASDAQ: CARA) and Vifor Pharma AG's Korsuva (difelikefalin) injection for severe-to-moderate pruritis (itching) in patients with chronic kidney disease (CKD) ...
Vifor Pharma and Cara Therapeutics announce U.S. FDA approval of KORSUVA™ injection for the treatment of moderate-to-...
ST. GALLEN, Switzerland & STAMFORD, Conn.--(BUSINESS WIRE)--Regulatory News: Vifor Pharma and Cara Therapeutics (Nasdaq:CARA) today announced that the U.S. Food and Drug Administration (FDA) has approve...
These 2 Stocks Just Soared After Hours Monday
After a record-setting day, the news for these two companies was icing on the cake.
Cara Therapeutics and Vifor Pharma announce U.S. FDA approval of KORSUVA™ (difelikefalin) injection for the treatment...
STAMFORD, Conn. and ST. GALLEN, Switzerland, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics (Nasdaq: CARA) and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has appr...
Is the Options Market Predicting a Spike in Cara Therapeutics (CARA) Stock?
Investors need to pay close attention to Cara Therapeutics (CARA) stock based on the movements in the options market lately.
Cara Therapeutics (CARA) Reports Q2 Loss, Misses Revenue Estimates
Cara (CARA) delivered earnings and revenue surprises of -10.91% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Cara Therapeutics: Q2 Earnings Insights
Shares of Cara Therapeutics (NASDAQ:CARA) decreased in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 12.96% year over year to ($0.61), which ...
Cara Therapeutics Reports Second Quarter 2021 Financial Results
– New Drug Application (NDA) Filing for KORSUVA™ Injection in CKD-aP under Priority Review by U.S. Food and Drug Administration (FDA); PDUFA Target Action Date August 23, 2021 –
Cara Therapeutics (CARA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cara Therapeutics to Announce Second Quarter 2021 Financial Results on August 9, 2021
STAMFORD, Conn., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to allevia...
How to Buy Biotech Stocks This Summer
It pays to know what could cause them to move and when.
Is Cara Therapeutics a Buy for Summer 2021?
The future of this troubled clinical-stage biotech rests on a single drug candidate that management hopes will treat an extremely common condition.
12 Cannabis Stocks That Lit Up Wall Street This Week
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues t...
Here Are the Cannabis Stocks That Caught Fire This Week
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues t...
Cara Therapeutics (CARA) Reports Q1 Loss, Misses Revenue Estimates
Cara (CARA) delivered earnings and revenue surprises of 24.19% and -80.94%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Cara Therapeutics: Q1 Earnings Insights
Shares of Cara Therapeutics (NASDAQ:CARA) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 24.19% year over year to ($0.47), which beat ...
Cara Therapeutics Reports First Quarter 2021 Financial Results
– U.S. Food and Drug Administration (FDA) Accepts New Drug Application (NDA) Filing and Grants Priority Review for KORSUVA™ Injection in CKD-aP –